^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
Trailblaze Pharos™

Company:
Roche
Type:
CE Marked
Related tests:
20d
Prospective study of the real impact of fusion centered genomic assays in patient management in a national collaborative group: the GETHI-XX-16 study. (PubMed)
Despite the growing knowledge of cancer biology and its translation to drug development, the overall impact of personalized treatments remains low. Access to comprehensive molecular tests covering properly all known actionable alterations and programs for a wide access to targeted therapies seem to be critical steps.
Journal
|
Trailblaze Pharos™ • FusionPlex® Dx • FusionPlex® Pan Solid Tumor v2 panel
4years
Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network. (PubMed, Ann Oncol)
"To address these challenges, the World Sarcoma Network convened two meetings of expert adult oncologists and pathologists, and subsequently developed this article to provide practical guidance on the management of patients with sarcoma harboring NTRK gene fusions. We propose a diagnostic strategy that considers disease stage and histologic and molecular subtypes to facilitate routine testing for TRK expression and subsequent testing for NTRK gene fusions."
Journal • Review
|
NTRK (Neurotrophic receptor tyrosine kinase)
|
NTRK fusion
|
Trailblaze Pharos™
|
Vitrakvi (larotrectinib) • Rozlytrek (entrectinib)